MDL IX definition

MDL IX means the MDL information exchange that receives and displays the tolerances, nominations, Scheduled Quantities, incentives and fees, certain notices and other information in relation to MDL’s operation of the open access regime for the Maui Pipeline and whose homepage is located at http.//www.mauipipeline.co.nz when accessed using the user name provided by MDL and the relevant password, or such other website as may be notified by MDL to each Shipper and Welded Party from time to time.
Sample 1Sample 2Sample 3

Examples of MDL IX in a sentence

  • Operating Code, of which the MDL IX is part, is substantially complete and ready for use.

  • Trading Running Operational Imbalances 12.1212.13 A Welded Party may trade the amount of its Running Operational Imbalance (or part of it) with any other Welded Party in accordance with the procedure on the MDL IX.

  • Trading Running Operational Imbalances 12.1712.13 A Welded Party may trade the amount of its Running Operational Imbalance (or part of it) with any other Welded Party in accordance with the procedure on the MDL IX.

  • Once the GIC has approved the queuing rules, MDL will notify all Shippers of the amount of AQ available for allocation on the MDL IX and distribute AQ in accordance with such approved queuing rules.6.57.5 Subject to section 7.6, a Shipper will pay the AQ Fee in relation to every Day, regardless of that Shipper’s Approved Nominations for that Day.

  • The April Change Request proposes amendments to section 4 (MDL IX) of the MPOC.

  • The April Change Request proposes changes that can be organised into three groups: Information on MDL IX (section 4);Prudential requirements (section 20); and Consequential changes and minor amendments.

  • The Master Contracts are available on the MDL IX and proposals are being sought from the industry for the supply of Put Secondary Balancing Gas.

  • The daily quantities of balancing gas purchased and sold by the Balancing Agent and the weighted average cost of the gas will be published on the MDL IX.

  • Table 2 Summary of opposing submissions Proposed change and rationaleSubmitterReason for submitter’s oppositionInformation on MDL IX (section 4)Sections 4.1 and 4.3 changed to provide: more transparency on Operational Imbalance, Running Operational Imbalance and Scheduled Quantities at each Welded Point.

  • This document, and the other documents referred to above, can be viewed and downloaded from the Publications menu of the MDL IX under the heading “Critical Contingency”.

Related to MDL IX

  • End User License Agreement means a license grant or end user license agreement governing software as further described in this Agreement or any applicable Appendix.

  • PTC means the tax credit for electricity produced from certain renewable generation resources described in Section 45 of the Internal Revenue Code of 1986, as it may be amended or supplemented from time to time.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Non-Microsoft Product means any third-party-branded software, data, service, website or product, unless incorporated by Microsoft in a Product.

  • NPC means Nevada Power Company, a Nevada corporation. ---

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • ISIS means the department’s individualized services information system.

  • Pfizer shall have the meaning set forth in the preamble.

  • Detailed manufacturing or process data means technical data that describe the steps, sequences, and conditions of manufacturing, processing or assembly used by the manufacturer to produce an item or component or to perform a process.

  • Beam axis means a line from the source through the centers of the x-ray fields.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • CMC means Comprehensive maintenance Contract (labour, spare and preventive maintenance)

  • Amplification, transmission and distribution equipment means, but is not limited to, production,

  • Company License Agreements means any license agreements granting any right to use or practice any rights under any Intellectual Property (except for such agreements for off-the-shelf products that are generally available for less than $25,000), and any written settlements relating to any Intellectual Property, to which the Company is a party or otherwise bound; and the term “Software” means any and all computer programs, including any and all software implementations of algorithms, models and methodologies, whether in source code or object code.

  • GSK has the meaning set forth in the preamble.

  • After-Acquired Intellectual Property has the meaning assigned to such term in Section 4.02(d).

  • Company Licensed IP means all Intellectual Property rights owned or purported to be owned by a third party and licensed to the Company or any Company Subsidiary or to which the Company or any Company Subsidiary otherwise has a right to use.

  • Sublicense Agreement means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any of the license rights granted to the Licensee under the Agreement.

  • Collaborative matter means a dispute, transaction, claim, problem, or issue for resolution, including a dispute, claim, or issue in a proceeding, that is described in a collaborative law participation agreement and arises under the family or domestic relations law of this state, including any of the following:

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Collaborative law process means a procedure intended to resolve a collaborative matter without intervention by a tribunal in which persons sign a collaborative law participation agreement and are represented by collaborative lawyers.

  • End User License means any license terms imposed by any Third Party Vendor on Customers and End Users. “Force Majeure Event” means an event or occurrence:

  • Licensor Technology means the Licensor Patents, the Licensor Know-How, Licensor Materials, and Non-Patent Rights Controlled by Licensor or its Affiliates embodied in Licensor Know-How or Licensor Materials.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.